Perspectives on HCV: Current Therapeutic Regimens and Drug-Drug Interactions
Author:
Affiliation:
1. Massachusetts General Hospital; Division of Infectious Diseases; Boston MA USA
2. Massachusetts General Hospital; Division of Gastroenterology; Boston MA USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmaceutical Science
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpdd.338/fullpdf
Reference50 articles.
1. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study;Lawitz;Lancet,2014
2. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study;Kwo;Hepatology,2016
3. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2);Lawitz;Hepatology,2016
4. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;N Engl J Med,2014
5. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection;Afdhal;N Engl J Med,2014
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective;European Journal of Medicinal Chemistry;2022-10
2. Position paper on the role of Internal Medicine in the management of hepatitis C virus infection (screening, diagnosis, linkage-to-care, treatment);Italian Journal of Medicine;2020-03-19
3. Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy;European Archives of Psychiatry and Clinical Neuroscience;2020-01-06
4. Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort;Open Forum Infectious Diseases;2019-01-01
5. Emerging New Therapies for Viral Hepatitis;Viral Hepatitis in Children;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3